Federation Nationale des Centers de Lutte Contre le Cancer grading of soft tissue sarcomas on needle core biopsies using surrogate markers

Lin, Xiaoqi; Davion, Simone; Bertsch, Elizabeth C.; Omar, Imran M.; Nayar, Ritu; Laskin, William B.

doi:10.1016/j.humpath.2016.06.008

Cited by 30 publications

(31 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main characteristics of the studies are summarized in Table . The publication year of the included studies ranged from 1998 to 2018.…”

Section: Resultsmentioning

confidence: 99%

“…The risk of bias assessment demonstrated a high risk of bias among the included studies (Fig. ) . All included trials were single‐center studies with a retrospective design, with the exception of 3 prospective studies .…”

Section: Resultsmentioning

confidence: 99%

“…Of these, 2 studies had cross‐sectional study designs with simultaneous CNB and IB or simultaneous CNB and FNA performed in the same individual . The clinical setting of the biopsy techniques was heterogeneous within and across studies (Table ) . Seven studies reported a single pathologist assessing the samples, whereas >1 pathologist was involved in 6 studies .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Core needle biopsy versus incisional biopsy for differentiation of soft‐tissue sarcomas: A systematic review and meta‐analysis

Birgin

Yang

Hetjens

et al. 2020

Cancer

View full text Add to dashboard Cite

BACKGROUND: Controversies exist regarding the biopsy technique of choice for the accurate diagnosis of soft-tissue sarcoma (STS). The objective of this systematic review and meta-analysis was to compare the diagnostic accuracy of core needle biopsy (CNB) versus incisional biopsy (IB) in STS with reference to the final histopathological result. METHODS: Studies regarding the diagnostic accuracy of CNB and IB in detecting STS were searched systematically in the MEDLINE and EMBASE databases. Estimates of sensitivity and specificity with associated 95% CIs for diagnostic accuracy were calculated. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2). RESULTS: A total of 17 studies comprising 2680 patients who underwent 1582 CNBs and 241 IBs with subsequent tumor resection met the inclusion criteria. The sensitivity and specificity of CNB and IB to detect the dignity of lesions were 97% (95% CI, 95%-98%) and 99% (95% CI, 97%-99%), respectively, and 96% (95% CI, 92%-99%) and 100% (95% CI, 94%-100%), respectively. Estimates of the sensitivity and specificity of CNB and IB to detect the STS histotype were 88% (95% CI, 86%-90%) and 77% (95% CI, 72%-81%), respectively, and 93% (95% CI, 87%-97%) and 65% (95% CI, 49%-78%), respectively. Patients who underwent CNB had a significantly reduced risk of complications compared with patients who underwent IB (risk ratio, 0.14; 95% CI, 0.03-0.56 [P ≤ .01). Quality assessment of studies revealed a high risk of bias. CONCLUSIONS: CNB has high accuracy in diagnosing the dignity of lesions and STS histotype in patients with suspected STS with fewer complications compared with IB. Therefore, CNB should be regarded as the primary biopsy technique.

show abstract

“…The main characteristics of the studies are summarized in Table . The publication year of the included studies ranged from 1998 to 2018.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Core needle biopsy versus incisional biopsy for differentiation of soft‐tissue sarcomas: A systematic review and meta‐analysis

Birgin

Yang

Hetjens

et al. 2020

Cancer

View full text Add to dashboard Cite

show abstract

“…The mitotic rate should be recorded. Because of tumour heterogeneity, a core biopsy may not provide accurate information about grade [36]. In addition, certain translocation-driven sarcomas have a relatively uniform cellular morphology and, as such, can be misleadingly scored as intermediate, rather than high grade.…”

Section: Referral and Assessmentmentioning

confidence: 99%

UK guidelines for the management of soft tissue sarcomas

Dangoor¹,

et al. 2016

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location means that developing evidence-based guidelines is complicated by the limitations of the data available. However, this makes it more important that STS are managed by teams, expert in such cases, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and the ongoing accumulation of further data and knowledge. The development of appropriate guidance, by an experienced panel referring to the evidence available, is therefore a useful foundation on which to build progress in the field. These guidelines are an update of the previous version published in 2010 (Grimer et al. in Sarcoma 2010:506182, 2010). The original guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices of the British Sarcoma Group (BSG) and were intended to provide a framework for the multidisciplinary care of patients with soft tissue sarcomas. This current version has been updated and amended with reference to other European and US guidance. There are specific recommendations for the management of selected subtypes of disease including retroperitoneal and uterine sarcomas, as well as aggressive fibromatosis (desmoid tumours) and other borderline tumours commonly managed by sarcoma services. An important aim in sarcoma management is early diagnosis and prompt referral. In the UK, any patient with a suspected soft tissue sarcoma should be referred to one of the specialist regional soft tissues sarcoma services, to be managed by a specialist sarcoma multidisciplinary team. Once the diagnosis has been confirmed using appropriate imaging, plus a biopsy, the main modality of management is usually surgical excision performed by a specialist surgeon. In tumours at higher risk of recurrence or metastasis pre- or post-operative radiotherapy should be considered. Systemic anti-cancer therapy (SACT) may be utilized in some cases where the histological subtype is considered more sensitive to systemic treatment. Regular follow-up is recommended to assess local control, development of metastatic disease, and any late-effects of treatment. For local recurrence, and more rarely in selected cases of metastatic disease, surgical resection would be considered. Treatment for metastases may include radiotherapy, or systemic therapy guided by the sarcoma subtype. In some cases, symptom control and palliative care support alone will be appropriate.

show abstract

“…Data from other types of sarcoma may not be directly applicable to GISTs, but, for example, mitotic counts in needle core biopsies taken from leiomyosarcoma are frequently smaller than counts obtained from excised tumour tissue [7]. Overestimation of the mitotic count from a needle core sample is rare, and needle core biopsy tissue assessment tends to underestimate also soft tissue sarcoma grade [7,8]. The risk for mitotic count underestimation might be the smaller the greater the number of needle biopsies taken, but this may not always be the case and taking of many needle core biopsies may not be feasible due to the anatomical localization of the tumour and the potential risks for tumour cell seeding and bleeding [7].…”

Section: Introductionmentioning

confidence: 99%

Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib

Joensuu

2019

COR

View full text Add to dashboard Cite

Preoperative imatinib is used frequently in the treatment of large localized GISTs to shrink the tumor prior to surgery. This approach may lead to challenges in the estimation of the risk of recurrence and the need of adjuvant imatinib, because the diagnosis is usually made from a needle biopsy with scant tissue for the assessment of GIST mitotic activity, a key prognostic factor. We propose a mitosis count multiplication method as a proxy for estimating the tumor mitotic count in select cases.

show abstract

Federation Nationale des Centers de Lutte Contre le Cancer grading of soft tissue sarcomas on needle core biopsies using surrogate markers

Cited by 30 publications

References 34 publications

Core needle biopsy versus incisional biopsy for differentiation of soft‐tissue sarcomas: A systematic review and meta‐analysis

Core needle biopsy versus incisional biopsy for differentiation of soft‐tissue sarcomas: A systematic review and meta‐analysis

UK guidelines for the management of soft tissue sarcomas

Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib

Contact Info

Product

Resources

About